Skip to main content
. Author manuscript; available in PMC: 2022 Mar 26.
Published in final edited form as: Lancet Infect Dis. 2018 Aug 17;18(10):1138–1149. doi: 10.1016/S1473-3099(18)30353-0

Figure 5. Community co-amoxiclav-resistant EC-UTIs (A), community EC-UTIs (B) and community urine samples submitted regardless of result (C) per 1000 patients per primary-care facility 2012-2016 compared with co-amoxiclav usage.

Figure 5

Footnote: showing one record per year per primary-care facility. For (A) the strongest predictor was co-amoxiclav DDD per 1000 patients per general practice in the previous year; for (B) and (C) the strongest predictor was co-amoxiclav DDD per 1000 patients per general practice in the current year. Spearman rho (and models) for each panel excludes 5 facilities which submitted less than 151 samples over 2011-2016 (all others submitted over 300). Spearman rho for univariable associations with previous vs current co-amoxiclav usage for the 3 outcomes left to right ρ=0.20 vs ρ=0.04, ρ=0.33 vs ρ=0.35, ρ=0.37 vs ρ=0.40 respectively.